

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



17th October 2024

Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ
Mumbai – 400001	Bandra (East), Mumbai – 400 051
Dalal Street,	C/1, G Block, Bandra Kurla Complex,
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Floor, Plot no.
BSE LIMITED	National Stock Exchange of India,

Sub.: Notice of Board Meeting

Ref.: Intimation under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations)

Dear Sirs/Madam,

Pursuant to Regulation 29 of the Listing Regulations, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Monday, 28th October 2024, to *inter-alia*, consider and approve unaudited consolidated and standalone financial results of the Company for the second quarter and half year ended 30th September 2024.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

Gaurang Shah

Sr. VP – Legal & Company Secretary